MeiraGTx (MGTX) Competitors $6.90 -0.14 (-1.99%) (As of 11:22 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends MGTX vs. HARP, CBMG, VYGR, FRLN, ARVN, IMCR, XNCR, SYRE, KNSA, and NTLAShould you be buying MeiraGTx stock or one of its competitors? The main competitors of MeiraGTx include Harpoon Therapeutics (HARP), Cellular Biomedicine Group (CBMG), Voyager Therapeutics (VYGR), Freeline Therapeutics (FRLN), Arvinas (ARVN), Immunocore (IMCR), Xencor (XNCR), Spyre Therapeutics (SYRE), Kiniksa Pharmaceuticals (KNSA), and Intellia Therapeutics (NTLA). These companies are all part of the "medical" sector. MeiraGTx vs. Harpoon Therapeutics Cellular Biomedicine Group Voyager Therapeutics Freeline Therapeutics Arvinas Immunocore Xencor Spyre Therapeutics Kiniksa Pharmaceuticals Intellia Therapeutics MeiraGTx (NASDAQ:MGTX) and Harpoon Therapeutics (NASDAQ:HARP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk and media sentiment. Is MGTX or HARP more profitable? Harpoon Therapeutics has a net margin of -81.68% compared to MeiraGTx's net margin of -1,146.81%. MeiraGTx's return on equity of -152.82% beat Harpoon Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MeiraGTx-1,146.81% -152.82% -56.41% Harpoon Therapeutics -81.68%-893.55%-45.98% Which has stronger valuation & earnings, MGTX or HARP? Harpoon Therapeutics has higher revenue and earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Harpoon Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMeiraGTx$8.12M55.13-$84.03M-$1.40-4.93Harpoon Therapeutics$37.34M10.43-$67.73M-$8.76-2.63 Do insiders and institutionals have more ownership in MGTX or HARP? 67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 74.0% of Harpoon Therapeutics shares are owned by institutional investors. 8.4% of MeiraGTx shares are owned by company insiders. Comparatively, 17.0% of Harpoon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, MGTX or HARP? MeiraGTx has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, Harpoon Therapeutics has a beta of 2.11, meaning that its stock price is 111% more volatile than the S&P 500. Does the media refer more to MGTX or HARP? In the previous week, MeiraGTx had 1 more articles in the media than Harpoon Therapeutics. MarketBeat recorded 1 mentions for MeiraGTx and 0 mentions for Harpoon Therapeutics. Harpoon Therapeutics' average media sentiment score of 0.53 beat MeiraGTx's score of 0.44 indicating that Harpoon Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment MeiraGTx Neutral Harpoon Therapeutics Positive Do analysts prefer MGTX or HARP? MeiraGTx currently has a consensus price target of $22.50, indicating a potential upside of 226.09%. Harpoon Therapeutics has a consensus price target of $23.00, indicating a potential downside of 0.04%. Given MeiraGTx's stronger consensus rating and higher probable upside, research analysts clearly believe MeiraGTx is more favorable than Harpoon Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MeiraGTx 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Harpoon Therapeutics 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the MarketBeat Community believe in MGTX or HARP? MeiraGTx received 95 more outperform votes than Harpoon Therapeutics when rated by MarketBeat users. Likewise, 71.32% of users gave MeiraGTx an outperform vote while only 59.12% of users gave Harpoon Therapeutics an outperform vote. CompanyUnderperformOutperformMeiraGTxOutperform Votes18971.32% Underperform Votes7628.68% Harpoon TherapeuticsOutperform Votes9459.12% Underperform Votes6540.88% SummaryMeiraGTx and Harpoon Therapeutics tied by winning 9 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Claim your FREE book now before it's too late! Get MeiraGTx News Delivered to You Automatically Sign up to receive the latest news and ratings for MGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGTX vs. The Competition Export to ExcelMetricMeiraGTxBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$447.80M$3.09B$5.18B$8.91BDividend YieldN/A1.76%4.98%4.03%P/E Ratio-4.9346.44135.1217.44Price / Sales55.13299.541,248.6491.11Price / CashN/A179.8138.8936.42Price / Book3.184.406.305.92Net Income-$84.03M-$42.42M$118.33M$224.86M7 Day Performance2.53%-3.93%-1.54%-0.45%1 Month Performance48.71%3.75%2.98%4.16%1 Year Performance42.56%36.20%36.39%27.33% MeiraGTx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGTXMeiraGTx4.4335 of 5 stars$6.90-2.0%$22.50+226.1%+48.8%$447.80M$8.12M-4.93300Gap UpHARPHarpoon Therapeutics0.8931 of 5 stars$23.01flat$23.000.0%N/A$389.61M$37.34M-2.6353CBMGCellular Biomedicine GroupN/AN/AN/AN/A$384.69M$340,000.00-6.98217VYGRVoyager Therapeutics4.5565 of 5 stars$6.59-1.5%$17.43+164.5%+6.5%$359.37M$143.77M9.28100Analyst ForecastGap UpFRLNFreeline TherapeuticsN/A$6.48flat$6.50+0.3%N/A$28.12MN/A-1.16152ARVNArvinas1.9741 of 5 stars$25.52+0.7%$60.00+135.1%+52.7%$1.75B$161.10M-5.46445Short Interest ↓IMCRImmunocore2.5999 of 5 stars$33.47-2.0%$69.18+106.7%-31.7%$1.67B$249.43M-35.23497Analyst DowngradeAnalyst RevisionXNCRXencor3.643 of 5 stars$23.74+0.6%$35.75+50.6%+38.5%$1.66B$168.34M-7.42280Insider SellingAnalyst RevisionSYRESpyre Therapeutics2.4719 of 5 stars$31.83-3.5%$48.57+52.6%N/A$1.64B$890,000.00-4.26100Analyst ForecastAnalyst RevisionNews CoverageKNSAKiniksa Pharmaceuticals2.1181 of 5 stars$22.39-1.0%$36.60+63.5%+48.8%$1.62B$270.26M-159.92220NTLAIntellia Therapeutics4.5714 of 5 stars$15.76-2.2%$55.36+251.3%-32.3%$1.61B$43.09M-2.90600Earnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies HARP Competitors CBMG Competitors VYGR Competitors FRLN Competitors ARVN Competitors IMCR Competitors XNCR Competitors SYRE Competitors KNSA Competitors NTLA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MGTX) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MeiraGTx Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share MeiraGTx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
